Urgent.News

the world's headlines, one feed

Editions

Health & Medicine

This Ebola outbreak has claimed over 2,000 lives. Here's why it is so hard to contain

(AP) -- More than 2,000 people have now died in the fastest-growing Ebola outbreak in history, and challenges keep coming in containing a rare type of

Over 2,000 lives have been lost in the deadliest Ebola outbreak since 2014, with the disease spreading at an alarming rate in a region plagued by conflict and logistical challenges. Congo's health authorities have confirmed 4,381 cases and 2,011 deaths, a death toll that has risen nearly three times faster than in the 2014-16 outbreak.

The outbreak's unique Bundibugyo strain, which has a higher fatality rate, has complicated efforts to contain it. Health teams navigate hazardous conditions, facing strikes by unpaid workers, rebel threats, and misinformation. The disease spreads through bodily fluids and contaminated surfaces, often exacerbated by traditional funeral practices.

The outbreak's location in volatile eastern Congo, near neighboring countries and a major city, makes it difficult to contain, as rebel attacks and mistrust hinder response efforts. International organizations are testing potential treatments, but the slow pace of clinical trials could delay effective care for affected patients.

Written by urgent.news from The Mainichi's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at mainichi.jp →

More in Health & Medicine

JW Pharmaceutical’s Gout Drug Candidate Outperforms Febuxostat in Phase 3 Trial

JW Pharmaceutical has reported positive results from a multinational Phase 3 trial of its gout drug candidate epaminurad (code name URC102), with the 6mg dose demonstrating statistically superior…

  • JW Pharmaceutical's epaminurad (URC102) outperformed febuxostat in Phase 3 gout trial.
  • Epaminurad achieved 50.0% serum uric acid reduction vs. 38.3% for febuxostat 40mg.
  • Safety profiles were comparable with no drug-related deaths reported.